AbbVie received FDA approval for Decnupaz (pivekimab sunirine) for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN), following its acquisition of ImmunoGen’s ADC program in 2023. The approval follows data from the Cadenza Phase 1/2 global study. The decision adds another CD123-targeting antibody-drug conjugate to the ultra-rare blood cancer landscape and supports AbbVie’s ADC strategy as it integrates acquired assets into late-stage development and commercialization plans. The approval is also a validation point for the ImmunoGen deal rationale, tying regulatory success to the company’s $10+ billion buyout consideration. For stakeholders, the key near-term items are label scope, uptake in treatment centers, and evidence refreshes that support duration and sequencing decisions in BPDCN care.